Navigation Links
Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceutical's Brintellix Has Blockbuster Potential
Date:8/1/2013

BURLINGTON, Mass., Aug. 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Lundbeck/Takeda Pharmaceutical's emerging antidepressant Brintellix will attain blockbuster status for unipolar depression* in the United States, France, Germany, Italy, Spain, United Kingdom and Japan by 2022. Brintellix is expected to be one of the most successful new agents in the unipolar depression market because of its potential for positive effects on cognition and its reasonably tolerable side effect profile demonstrated to date. Decision Resources expects Lundbeck and Takeda to position Brintellix as a first-line option for elderly patients with depression and as a second-line therapy in patients who fail a generic selective serotonin reuptake inhibitor (SSRI).

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Unipolar Depression finds that major-market sales in the unipolar depression market will decline by 30 percent from 2012-2022 owing to the generic entry of the blockbuster drugs escitalopram (Lundbeck's Cipralex/Seroplex, other manufacturers, Forest Laboratories' Lexapro, generics; Lundbeck/Mochida Pharmaceuticals/Mitsubishi Tanabe Pharma's Lexapro), Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Eli Lilly/Shionogi's Cymbalta/Xeristar, as well as expanded generic competition for venlafaxine XR (Pfizer/Almirall's Effexor XR, other manufacturers, generics). The launch of Brintellix and two other emerging antidepressants by 2022—Eli Lilly's edivoxetine and Forest Laboratories/Pierre Fabre's Fetzima—will be insufficient to counteract this decline; edivoxetine and Fetzima will together reach just under $1 billion in sales across the major markets by 2022.

Furthermore, the atypical antipsychotic drug class will experience significant loss of sales in the unipolar depression market owing to continued generic erosion of key agents and, including generic competition to Abilify. Consequently, major-market sales of this drug class will drop by half, to just under $1 billion in 2022. The forecasted launch of Otsuka/Lundbeck's brexpiprazole and the expanded use of Dainippon Sumitomo Pharma/Sunovion/Takeda's Latuda across the major markets will only partially offset the forthcoming decline in drug class sales.

"In a highly genericized and fragmented market, in which SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs) are and will remain deeply entrenched first-line agents, the uptake of emerging therapies among physicians will be highly dependent on their successful differentiation from currently available SSRIs and SNRIs," said Decision Resources Senior Business Insights Analyst Alana K. Simorellis, Ph.D. "An agent benefitting patients who fail to respond to current treatments or one that treats residual symptoms of depression represent opportunities for drug developers. An antidepressant or antipsychotic proven to be more effective in treatment-resistant patients would quickly gain physician acceptance and experience use, likely as part of an augmentation strategy."

*Unipolar depression encompasses major depressive disorder, minor depression and dysthymia.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
2. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
3. Imaging Healthcare Specialists Among the First in the Nation to Offer Imaging Diagnosis for Alzheimers Disease
4. Advanced Radiology Among the First in the U.S. to Offer New Alzheimers Disease Tracer
5. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
6. Frost & Sullivan: Miniaturization of Medical Devices Reduces Mortality Rates among Cardiac Dysrhythmia Patients
7. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
8. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
9. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
10. GNC NutriWater, COTYs Beyonce Pulse NYC, Swansons Super DPA Fish Oil, Among First SupplySide Insights Awards Finalists
11. Poorest U.S. States Rank Among Most Wasteful in Unnecessary Medication-Related Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):